Formerly known as Chanrx Corp., Laguna Pharmaceuticals Inc. raised $30 million in series B money for phase III work in atrial fibrillation (AF) and atrial flutter with vanoxerine, moving operations from Cleveland to San Diego while bringing aboard as CEO well-known biotech player Bob Baltera.